Hormone Receptors and Epithelial Ovarian Cancer: Recent Advances in Biology and Treatment Options
Fulvio Borella,
Stefano Fucina,
Luca Mangherini,
Stefano Cosma,
Andrea Roberto Carosso,
Jessica Cusato,
Paola Cassoni,
Luca Bertero,
Dionyssios Katsaros,
Chiara Benedetto
Affiliations
Fulvio Borella
Gynecology and Obstetrics 1U, Departments of Surgical Sciences, City of Health and Science, University of Turin, 10126 Turin, Italy
Stefano Fucina
Gynecology and Obstetrics 1U, Departments of Surgical Sciences, City of Health and Science, University of Turin, 10126 Turin, Italy
Luca Mangherini
Pathology Unit, Department of Medical Sciences, University of Turin, 10126 Turin, Italy
Stefano Cosma
Gynecology and Obstetrics 1U, Departments of Surgical Sciences, City of Health and Science, University of Turin, 10126 Turin, Italy
Andrea Roberto Carosso
Gynecology and Obstetrics 1U, Departments of Surgical Sciences, City of Health and Science, University of Turin, 10126 Turin, Italy
Jessica Cusato
Laboratory of Clinical Pharmacology and Pharmacogenetics, Department of Medical Sciences, Amedeo di Savoia Hospital, University of Turin, 10149 Turin, Italy
Paola Cassoni
Pathology Unit, Department of Medical Sciences, University of Turin, 10126 Turin, Italy
Luca Bertero
Pathology Unit, Department of Medical Sciences, University of Turin, 10126 Turin, Italy
Dionyssios Katsaros
Gynecology and Obstetrics 1U, Departments of Surgical Sciences, City of Health and Science, University of Turin, 10126 Turin, Italy
Chiara Benedetto
Gynecology and Obstetrics 1U, Departments of Surgical Sciences, City of Health and Science, University of Turin, 10126 Turin, Italy
Epithelial ovarian cancer (EOC) is a significant cause of cancer-related mortality in women. Despite advances in diagnosis and treatment, EOC remains a challenging disease to manage, and the 5-year survival rate is still poor. The role of hormone receptors (HRs) in EOC carcinogenesis and prognosis has been actively explored; however, the role of hormone therapy (HT) in the treatment of these tumors is not well established. Most available data on HT mainly come from retrospective series and small early clinical trials. Several of these studies suggest that HT may have a role in adjuvant, maintenance therapy, or in the case of recurrent disease, especially for some subtypes of EOC (e.g., low-grade serous EOC). Furthermore, HT has recently been combined with targeted therapies, but most studies evaluating these combinations are still ongoing. The main aim of this review is to provide an overview of the progress made in the last decade to characterize the biological and prognostic role of HRs for EOC and the developments in their therapeutic targeting through HT.
